AbGn 7

Drug Profile

AbGn 7

Alternative Names: AbGn-7

Latest Information Update: 25 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AbGenomics Corporation
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Solid tumours

Most Recent Events

  • 31 Jan 2013 AbGenomics completes a phase Ia/b trial in Solid tumours (late-stage disease, second-line therapy or greater) including Gastric cancer (combination therapy, late-stage disease) in USA and Taiwan (NCT01466569)
  • 04 Jun 2012 Phase-I clinical trials in Gastric cancer (combination therapy, late-stage disease) in Taiwan (IV)
  • 04 Jun 2012 Phase-I clinical trials in Solid tumours (combination therapy, late-stage disease) in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top